DBS for Intractable OCD: Lessons for Integrating Clinical Practice of Psychiatrists, Neurosurgeons, and Psychologists

Needs Statement

Patients with severe obsessive-compulsive disorder (OCD) who have failed to respond to a range of conventional therapies may benefit from deep brain stimulation (DBS), which is available under a Humanitarian Device Exemption (HDE) from the FDA. Obstacles to employing this treatment option, however, include lack of knowledge about patient selection, surgical techniques, and DBS programming. Attendees will learn about patient selection for DBS, assessment, surgical planning, and programming -- all information needed for enhancing clinical outcomes.

Educational Objectives

At the conclusion of the conference, participants should be able to:

• Apply the inclusion and exclusion criteria for eligibility of patients with OCD to undergo DBS
• Define the role of cognitive behavioral therapy, specifically ERP, in the assessment of candidates for DBS
• List the benefits of re-introducing cognitive behavioral therapy, specifically ERP, after DBS
• Describing the techniques and challenges in conducting DBS programming for OCD

Target Audience

Accreditation/Credit Designation

Baylor College of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Baylor College of Medicine designates this live activity for a maximum of 6.50 AMA PRA Category 1 Credit™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy

Baylor College of Medicine (BCM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians. BCM is committed to sponsoring CE activities that are scientifically based, accurate, current, and objectively presented.

In accordance with the ACCME Standards for Commercial Support, BCM has implemented a mechanism requiring everyone in a position to control the content of an educational activity (i.e., directors, planning committee members, faculty) to disclose any relevant financial relationships with commercial interests (drug/device companies) and manage/resolve any conflicts of interest prior to the activity. Individuals must disclose to participants the existence or non-existence of financial relationships at the time of the activity or within 24 months prior.

In addition, BCM has requested activity faculty/presenters to disclose to participants any unlabeled use or investigational use of pharmaceutical/device products; to use scientific or generic names (not trade names) in referring to products; and, if necessary to use a trade name, to use the names of similar products or those within a class. Faculty/presenters have also been requested to adhere to the ACCME's validation of clinical content statements.

BCM does not view the existence of financial relationships with commercial interests as implying bias or decreasing the value of a presentation. It is up to participants to determine whether the relationships influence the activity faculty with regard to exposition or conclusions. If at any time during this activity you feel that there has been commercial/promotional bias, notify the Activity Director or Activity Coordinator. Please answer the questions about balance and objectivity in the activity evaluation candidly.

All of the relevant financial relationships listed for these individuals have been mitigated.